Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Astra and Merck & Co present mixed small-cell lung cancer data, while Innovent, Xencor, Alphamab and Alligator bang the drum for CTLA-4.
Almost in stealth mode the Swiss firm moves to begin a huge pivotal programme rivalling that of the IDO and IL-2 mechanisms.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?